Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Our popular solutions

Key benefits:

Direct access to your target Pharma audience
A cohesive marketing campaign
Effective reporting

View all content

Generics Bulletin

Corporate Strategies of the biggest Generics and Biosimilar players

17 Sep 2019

Understand the latest Corporate Strategies of the biggest Generics and Biosimilar players.

Topic Business strategies

Single report
Scrip

Inclisiran’s Safety Data Suggest Game-Changing Potential In PCSK9 Market

By Joseph Haas 11 Sep 2019

The Medicines Co. unveiled Phase III safety data for inclisiran showing safety and tolerability comparable to placebo and efficacy in line with the PCSK9 inhibitor class – which should be the reassurance it needs for the oral agent.

Topic Drug development landscape Drug review

View article
Scrip

Interview: AstraZeneca’s Pangalos on Landmark DAPA-HF Resultsv

By Eleanor Malone 11 Sep 2019

AstraZeneca’s head of R&D spoke to Scrip about the outstanding results for dapagliflozin in heart failure regardless of diabetes status.

Topic Company analysis Diabetes

View article
Scrip

Anima Biotech Lighting The Way In Protein Translation

By Jo Shorthouse 10 Sep 2019

Emerging Company Profile: With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light.

Topic Clinical trials

View article
Biomedtracker

Biomedtracker: Improved Custom Company Portfolio Feature

04 Sep 2019

Discover how creating custom company portfolios can help you overcome your toughest business challenges.

Topic Business strategies

Single report
Generics Bulletin

Executive and market moves interviews for exclusive insider knowledge

04 Sep 2019

Get in the side track on the Generics market with executive and market-moves interviews for exclusive insider knowledge.

Topic Business strategies

Single report
Generics Bulletin

Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

By Aidan Fry 15 Aug 2019

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Topic Business strategies

View article
Scrip

An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

By Mandy Jackson 15 Aug 2019

The US FDA informed the company it will convene an advisory committee meeting to review the REDUCE-IT sNDA for the proprietary fish oil pill, delaying the approval by at least three months and surprising investors.

Topic FDA Drug approval

View article
Scrip

Taltz Tops Tremfya In Head-To-Head Psoriasis Study On Complete Skin Clearance

By Jessica Merrill 15 Aug 2019

Lilly's IL-17A inhibitor ixekizumab outperformed J&J's IL-23 inhibitor guselkumab on achieving complete skin clearance in moderate-to-severe psoriasis patients at 12 weeks in a head-to-head trial.

Topic Clinical trials

View article
Generics Bulletin

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

By David Wallace 14 Aug 2019

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Topic Company analysis

View article
Scrip

Oncology Market Leaders Maintain Their Upper Hand

By Jessica Merrill 14 Aug 2019

Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.

Topic Drug development landscape Drug review

View article
Scrip

The Chinese Pharma Market: Insights in turbulent times

12 Aug 2019

With the continuation of the US-China trade standoff, the rapid increase in R&D costs and a gruelling centralized bidding process, foreign pharma firms have a lot on their plates in China. Gain insight on these key challenges through this Scrip article pack

Topic Business strategies

Single report
Trialtrove

Trialtrove 2018 Completed Clinical Trials Snapshot

12 Aug 2019

Get a visual snapshot of how the industry pipelines are faring with our 2018 Completed Trials snapshot. This graphic analysis paints a clear picture of the state of clinical trial completions, while pointing to some important changes that are emerging.

Topic Clinical trials Drug development landscape

Single report
Generics Bulletin

Reddy's Will Look For Acquisitions Under New CEO Israeli

By Aidan Fry 09 Aug 2019

With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.

Topic Business strategies

View article
HBW Insight

Japan's New Rx-To-OTC Procedure Exacerbating Switch Blockage Says JSMI

By David Ridley 07 Aug 2019

Japan's new Rx-to-OTC switch procedure has exacerbated a "switch lag" compared with developed countries, says Japan Self-Medication Industry senior adviser Toshi Tominaga in an exclusive interview with HBW Insight. Tominaga proposes improvements such as self-care education for consumers and drug usage advice included by firms in switch applications to help balance the risk-benefit decisions of expert judges.

Topic Policy and regulation

View article

Latest headlines

Scrip

20 Sep 2019

Pipeline Watch: Phase II Starts In Hearing Loss, Type 1 Diabetes

Link
Scrip

20 Sep 2019

Gene Profiling Identifies Drugs For Childhood Cancers But Access A Problem

Link
Scrip

20 Sep 2019

Emmaus Fumes After EMA Rejects Sickle Cell Drug Again

Link
Scrip

20 Sep 2019

Brighter News For Varlitinib As Results In Tough Cancer Type Encourage ASLAN

Link
Scrip

19 Sep 2019

ARIBIO Counts On Multi-Modal Drug For Alzheimer's And Vascular Dementia

Link
Scrip

19 Sep 2019

What’s At Stake As China Expands '4+7' Scheme: An Infographic Snapshot

Link
Scrip

19 Sep 2019

Boundless Bio Launches With $46m And Novel Oncology Focus On Extrachromosomal DNA

Link
Scrip

19 Sep 2019

ESMO Preview: Five Key Oncology Battlegrounds To Watch

Link
Scrip

19 Sep 2019

J&J's Erleada Approved By FDA In New Prostate Cancer Indication

Link
Scrip

19 Sep 2019

Themis CEO: Chikungunya Vaccine Could Be Approved In Two Years

Link
Scrip

19 Sep 2019

Novartis Says SMA Baby Death Not Due To Zolgensma

Link
Scrip

19 Sep 2019

Ten Strategies For Success In Antibody-Drug Conjugate Development

Link
Scrip

18 Sep 2019

Cynata In Potential Japan Double As Fujifilm Acquires Lead Asset

Link
Scrip

18 Sep 2019

Bayer Aims To Take AI-Driven One Drop Beyond Diabetes

Link
Scrip

18 Sep 2019

Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

The partner of choice for pharmaceutical companies

Get drugs to market faster

Our unique strengths

Identify market opportunities

Capitalize on treatment trends

Approach reimbursement proactively

View competitor activity

Relevant products

Below are the Product List

Awareness

Thought leadership

Our popular solutions

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store